Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).

被引：0
|
作者：
Khaki, Ali Raza [1 ]
Shan, Yong [2 ]
Nelson, Richard [3 ]
Kaul, Sapna [2 ]
Gore, John L. [1 ]
Grivas, Petros [1 ]
Williams, Stephen B. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Texas Med Branch, Galveston, TX 77555 USA
[3] Univ Utah, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant cisplatin-based chemotherapy in patients with ureteral obstruction secondary to muscle invasive bladder cancer
    Strother, Marshall
    Kutikov, Alexander
    Lewis, Bianca
    Deng, Mengying
    Handorf, Elizabeth A.
    Epstein, Matthew
    Ghatalia, Pooja
    Greenberg, Richard E.
    Chen, David
    Viterbo, Rosalia
    Anari, Fern
    Smaldone, Marc C.
    Zibelman, Matthew R.
    Uzzo, Robert Guy
    Plimack, Elizabeth R.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
    Gust, Kilian M.
    Rebhan, Katharina
    Resch, Irene
    Shariat, Shahrokh F.
    Necchi, Andrea
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 547 - 556
  • [43] Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
    Pietzak, Eugene J.
    Zabor, Emily C.
    Bagrodia, Aditya
    Armenia, Joshua
    Hu, Wenhuo
    Zehir, Ahmet
    Funt, Samuel
    Audenet, Francois
    Barron, David
    Maamouri, Noelia
    Li, Qiang
    Teo, Min Yuen
    Arcila, Maria E.
    Berger, Michael F.
    Schultz, Nikolaus
    Dalbagni, Guido
    Herr, Harry W.
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Al-Ahmadie, Hikmat
    Bochner, Bernard H.
    Solit, David B.
    Iyer, Gopa
    EUROPEAN UROLOGY, 2019, 75 (02) : 231 - 239
  • [44] Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgery
    Chanza, Nieves Martinez
    Hamid, Anis
    Salgado, Roberto
    Gevaert, Thomas
    Maetens, Marion
    Rorive, Sandrine
    Aftimos, Philippe Georges
    Sideris, Spyridon
    Gil, Thierry
    Awada, Ahmad
    Roumeguere, Thierry Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis
    Jue, Joshua S.
    Koru-Sengul, Tulay
    Miao, Feng
    Velasquez, Maria C.
    Savio, Luis F.
    Alameddine, Mahmoud
    Kroeger, Zachary A.
    Punnen, Sanoj
    Parekh, Dipen J.
    Ritch, Chad R.
    Gonzalgo, Mark L.
    MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (05): : 572 - 580
  • [46] Three versus four cycles of neoadjuvant gemcitabine cisplatin for muscle invasive bladder cancer (MIBC).
    Major, Catherine Kendall
    Williams, Michael Brandon
    Fleming, Mark T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Neutrophil extracellular trap as a predictive marker to cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer
    Shang, Bing-Qing
    Gu, Zhaoru
    Qu, Wang
    Xie, Rui-Yang
    Wu, Jie
    Zhou, Ai-Ping
    Shou, Jianzhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    EUROPEAN UROLOGY, 2019, 75 (04) : 694 - 694
  • [49] OUTCOME OF NON-RESPONDERS TO NEOADJUVANT IMMUNOTHERAPY COMPARED TO CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY IN MUSCLE-INVASIVE BLADDER CANCER
    Bandini, Marco
    Zaffuto, Emanuele
    Marandino, Laura
    Scuderi, Simone
    Pederzoli, Filippo
    Raggi, Daniele
    Salonia, Andrea
    Gandaglia, Giorgio
    Comana, Sabrina
    Barletta, Francesco
    Pellegrino, Antony
    Giusy, Burgio
    Moschini, Marco
    Fossati, Nicola
    Briganti, Alberto
    Montorsi, Francesco
    Colombo, Renzo
    Necchi, Andrea
    Gallina, Andrea
    JOURNAL OF UROLOGY, 2020, 203 : E840 - E840
  • [50] Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2019, 202 (01): : 30 - 30
12345